Oral antidiabetic agents in type 2 diabetes

Current Medical Research and Opinion

Volumn 23, Issue 4, 2007, Pages 945-952

  Levetan, Claresa ^a  

^a LANKENAU HOSPITAL   (United States)

Author keywords

Dipeptidyl peptidase 4 inhibitors; Glucagon like peptide 1; Type 2 diabetes

Indexed keywords

ACARBOSE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AFFECTING AGENT; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; LIVER ENZYME; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PHENFORMIN; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG; VILDAGLIPTIN; VOGLIBOSE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; BINDING AFFINITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG BINDING; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; EDEMA; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; IN VITRO STUDY; INSULIN RELEASE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LIVER TOXICITY; MALAISE; MEDLINE; MONOTHERAPY; MORTALITY; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PERIPHERAL EDEMA; RESPIRATORY DISTRESS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SOMNOLENCE; TREATMENT FAILURE; WEIGHT GAIN;

ADENOSINE DEAMINASE; ADMINISTRATION, ORAL; ALPHA-GLUCOSIDASES; ANTIGENS, CD26; BENZAMIDES; BIGUANIDES; DIABETES MELLITUS, TYPE 2; GLYCOPROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; RECEPTORS, GLUCAGON; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 34247357752     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X178766     Document Type: Review

References (69)

1. Steppel JH, Horton ES. Beta-cell failure in the pathogenesis of type 2 diabetes mellitus. Curr Diab Rep 2004;4:169-75
2. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
3. Deacon CF, Ahrén B, Holst JJ. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin Investig Drugs 2004;13:1091-102
4. Ahrén B. Inhibition of dipeptidyl peptidase-4 (DPP-4) - a novel approach to treat type 2 diabetes. Curr Enzyme Inhibition 2005;1:65-73
5. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 2005;48:612-15
6. Ahrén B. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Drugs 2006 15:431-42
7. Bell DSH. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy. Clin Ther 2004;26:1714-27
8. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004;64:1339-58
9. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002;287:360-72
10. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005;65:385-411
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
12. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93
13. Kahn SE, Haffner SM, Heiser MA, et al., for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
14. Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrin Metab Clin North Am 2001;30:909-33
15. Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997;26:511-21
16. Klimt CR, Knatterud GL, Meinert CL, Prout TE. The University Group Diabetes Program: a study of the effect of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. I. Design, methods, and baseline characteristics. II. Mortality results. Diabetes 1970;19(Suppl 2):747-830
17. Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998;47:345-51
18. Rosenstock J, Hassman DR, Madder RD, et al., for the Repaglinide Versus Nateglinide Comparison Study Group. Diabetes Care 2004;27:1265-70
19. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
20. Diabetes Prevention Program Research Group. Reduction of the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
21. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12
22. Misbin RL. The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care 2004;27:1791-3
23. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
24. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. Diabetes Care 2004;27:256-63
25. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular event in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomized controlled trial. Lancet 2005;366:1279-89
26. Yki-Järvinen H. The PROactive study: some answers, many questions. Lancet 2005;366:1241-2
27. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for the prevention of diabetes mellitus the STOP-NIDDM randomized trial. STOP-NIDDM Research Group. JAMA 2003;290:486-94
28. Drucker D. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929-40
29. Ahrén B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004;36:867-76
30. Ahrén B, Landin-Olsson M, Jansson P-A, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89:2078-84
31. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199-206
32. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of beta-cell proliferation and inhibition of apoptosis. Endocrinology 2003;144:5145-8
33. Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozocin-induced diabetic rats. Diabetes 2003;52:741-50
34. Duttaroy A, Voelker F, Merriam K, et al. The DPP-4 inhibitor vildagliptin increases pancreatic beta-cell neogenesis and decreases apoptosis [abstract]. Presented at: American Diabetes Association - 65th Scientific Sessions; June 10-14, 2005; San Diego, Calif. Abstract 572-P
35. Ahrén B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF 237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27:2874-80
36. Deacon CF. MK-431 (Merck). Curr Opin Investig Drugs 2005;6:419-26
37. Mari A, Sallas M, He YL, et al. Vildagliptin, a dipetidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4888-94
38. Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006;46:876-86
39. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006;60:1454-70
40. Kendall DM, Kim D, Maggs D. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. Diabetes Technol Ther 2006;8:385-96
41. Miller SA, Onge EL. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother 2006;40:1336-43
42. Ahrén B, Pacini G, Foley J, et al. Improved meal-related β-cell function and insulin sensitivity by the dipetidyl peptidase IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936-40
43. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7
44. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43
45. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19
46. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71
47. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Hormone Metab Res 2007, in press
48. Rosenstock J, Baron M, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007;30:217-23
49. Dejager S, Lebeaut A, Couturier A, et al. Sustained reduction in HBA1c during one-year treatment with vildaglitin in patients with type 2 diabetes (T2DM) [abstract]. Diabetes 2006;55(Suppl 1):A29. Abstract 120-OR
50. Nathwani A. The use of vildagliptin for treatment of patients with type 2 diabetes mellitus [abstract]. Presented at: American Diabetes Association - 66th Scientific Sessions, June 9-13, 2006; Washington, DC
51. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone tiierapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-68
52. Stein P. Sitagliptin: a novel dipeptidyl peptidase-4 inhibitor for the treatment of patients with type 2 diabetes [abstract]. Presented at: American Diabetes Association - 66th Scientific Sessions; June 9-13, 2006; Washington, DC
53. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007, published online 2 February 2007, doi:10.2337/dc06-1732
54. Rosenstock J, Baron MA, Camisasca R-P, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:175-85
55. Fonseca V, Dejager S, Albrecht D, et al. Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM) [abstract]. Diabetes 2006;55(Suppl 1):A111. Abstract 467-P
56. Matikainen N, Manttari S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006;49:2049-57
57. Nathwani A, Lebeaut A, Byiers S, et al. Reduction in blood pressure in patients treated with vildagliptin as monotherapy or in combination with metformin for type 2 diabetes [abstract]. Diabetes 2006;55(Suppl 1):A113. Abstract 474-P
58. He YL, Sabo R, Wang Y, et al. The influence of hepatic impairment on the pharmacokinetics of vildagliptin [abstract]. Diabetes 2006;55(Suppl 1):A469. Abstract 2024-PO
59. He YL, Sabo R, Wang Y. Influence of age, gender and BMI on the pharmacokinetics and pharmacodynamics of vildagliptin [abstract]. Clin Pharm Ther 2006;79:P63. Abstract PIII-19
60. Januvia [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2006
61. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006;29:435-49
62. Buse JB, Henry RR, Han J, et al., for the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
63. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
64. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
65. Ratner RE, Maggs D, Nielsen LL, et al. Long term effects of exenatide therapy over 82 weeks in over-weight metformin-treated patients with type 2 diabetes mellitus. Diab Obes Metab 2006;419-28
66. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559-69
67. Byetta [package insert]. San Diego, Calif: Amylin Pharmaceuticals Inc.; 2006
68. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide significantly improves glycemic control, and lowers body weight without risk of either major or minor hypoglycemic episodes in subject with type 2 diabetes [abstract]. Diabetes 2006;55(Suppl 1):A462. Abstract A27-28, Abstract 115-OR
69. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide treatment, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotiierapy study [abstract]. Diabetes 2006;55(Suppl 1):A465. Abstract 2007-PO